Notably, clinical translation of these insights includes the RNA polymerase I inhibitor CX-5461, which selectively downregulates menin and LEDGF, induces AML cell differentiation, and, critically, has demonstrated acceptable tolerability without neutropenia in early-phase hematologic trials [117]. This evidence concerns the gene MEN1 and acute myeloid leukemia.